Hospital Injectable Products · LP-190
Hyoscine butylbromide Injection
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-190Hospital Injectable Products
- Generic identity
- Hyoscine butylbromideInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-190
- Generic identity
- Hyoscine butylbromide
- Presentation
- Injection
- Catalogue strength
- 20 mg/mL
- Catalogue pack
- Ampoule 1 mL; carton 10 ampoules
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Hyoscine butylbromide.
- Dosage form: Injection.
- Catalogue strength / concentration: 20 mg/mL.
- Catalogue pack: Ampoule 1 mL; carton 10 ampoules.
- Catalogue category: Hospital Injectable Products; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Sterile formulation, route(s) of administration, pH/osmolality where applicable and ampoule specification.
- Dilution/compatibility, administration rate, monitoring and resuscitation requirements for the exact label.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 20 mg/mL | Injection | — | Ampoule 1 mL; carton 10 ampoules | Do not infer IV/IM/SC route, dilution, rate or compatibility from concentration and ampoule size alone. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Hyoscine butylbromide is an antimuscarinic antispasmodic used in selected smooth-muscle spasm and procedural contexts. It is a different chemical form from hyoscine hydrobromide products used for other purposes. The injectable presentation carries safety considerations that differ from an oral tablet. An ingredient catalogue does not establish that unexplained abdominal pain is an appropriate reason for administration.
Clinical context and therapeutic role
Professional assessment identifies the likely cause of pain or spasm and excludes conditions requiring urgent investigation. Injection may be used in a monitored setting for specific acute or diagnostic indications under an authorized label. It should not mask worsening illness or replace evaluation of obstruction, infection or other serious disease. The MHRA safety communication is directly relevant to injectable hyoscine butylbromide and highlights the need to consider underlying cardiac disease.
Selected safety context
Tachycardia, hypotension and anaphylaxis can occur and can be particularly serious in people with cardiac disease. The MHRA advises monitoring at-risk patients and ensuring trained staff and resuscitation equipment are available. Antimuscarinic effects can include urinary retention, dry mouth and visual disturbance. Glaucoma, relevant gastrointestinal obstruction and other contraindications require label-specific review. New chest symptoms, collapse or a severe allergic reaction needs immediate medical attention.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The source lists a 20 mg/mL ampoule of hyoscine butylbromide. Verify exact chemical identity and authorized routes. Do not substitute a hydrobromide formulation or infer excipients, compatibility or injection instructions from a product with a related name.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Confirm the cause of symptoms or procedural purpose, cardiac history, contraindications and monitoring capacity. Check the exact injectable label and current safety updates.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MHRA: hyoscine butylbromide injection cardiac safetyArchived source classification: government or public health guidance | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-190.
Professional enquiries
Request product-specific evidence for LP-190.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.